CYTK - Cytokinetics, Incorporated
| Previous Close | 13.05 |
| Open | 13.07 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 900 |
| Day's Range | 12.85 - 13.48 |
| 52 Week Range | 5.75 - 14.94 |
| Volume | 383,313 |
| Avg. Volume | 439,323 |
| Market Cap | 779.908M |
| Beta (3Y Monthly) | 1.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.98 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.17 |
- GlobeNewswire
Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting
Cytokinetics, Incorporated (CYTK) today announced data from the Phase 1 study of CK-3773274 (CK-274) were presented in a poster session at the HFSA 23rd Annual Scientific Meeting in Philadelphia. The study met its primary and secondary objectives to assess the safety and tolerability of single and multiple oral doses of CK-274, describe the pharmacokinetics (PK) of CK-274 and its pharmacodynamic effects (PD) as measured by echocardiography, as well as to characterize the PK/PD relationship with regards to cardiac function.
- GlobeNewswire
Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2019 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two poster presentations at the 23rd Annual Heart Failure Society of.
- GlobeNewswire
Cytokinetics to Present at September Investor Conferences
Interested parties may access the live webcast of these presentations by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of each presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of each event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
- Simply Wall St.
Is Cytokinetics (NASDAQ:CYTK) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- GlobeNewswire
Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
Cure SMA and Cytokinetics (CYTK) today announced the renewal of their partnership to increase education, awareness, public policy and fundraising for spinal muscular atrophy (SMA). Cytokinetics will lend support for several of Cure SMA’s upcoming initiatives at the national level and continues to support and participate in events in its local community throughout the year. Cytokinetics remains committed to serving the interests of patients and caregivers fighting SMA, a genetic disease that robs people of their physical strength and can take away their ability to walk, eat or breathe. This year Cytokinetics was a Platinum Sponsor of the 2019 Annual SMA Conference, a unique event that brings together families affected by SMA, along with researchers and clinicians, to network, learn, and collaborate.
- Thomson Reuters StreetEvents
Edited Transcript of CYTK earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 Cytokinetics Inc Earnings Call
Motley FoolCytokinetics Inc (CYTK) Q2 2019 Earnings Call Transcript
CYTK earnings call for the period ending June 30, 2019.
- Zacks
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -5.66% and 4.88%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cytokinetics Reports Second Quarter 2019 Financial Results
Completed Enrollment in GALACTIC-HF with More than 8,200 Heart Failure Patients Results from Phase 1 Study of CK-274 to be Presented at HFSA in September 2019; Phase 2 Clinical.
- Zacks
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
Cytokinetics, Incorporated (CYTK) today announced that preclinical data for CK-3773274 (CK-274) were presented at the American Heart Association’s Basic Cardiovascular Sciences (BCVS) Scientific Sessions in Boston, showing that CK-274 decreased cardiac contractility in vitro, in vivo in healthy animals, and in vivo in a mouse model of hypertrophic cardiomyopathy (HCM). CK-274 is a novel cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of HCM which may result from increased cardiac contractility.
- American City Business Journals
Health Care Digest: Kilroy's Oyster Point mystery, helping researchers ditch spreadsheets — and more
Biotech real estate developer Kilroy is happy with leasing at its 2.5 million-square-foot Oyster Point project, a fast-growing San Francisco tech company is moving researchers off paper — and more in our Health Care Digest.
- Simply Wall St.
Does Cytokinetics, Incorporated (NASDAQ:CYTK) Have A Volatile Share Price?
If you own shares in Cytokinetics, Incorporated (NASDAQ:CYTK) then it's worth thinking about how it contributes to the...
- American City Business Journals
First big lease lands at Kilroy's huge Oyster Point project
Years in the making — and still two years from opening — Kilroy Oyster Point lines up its first lease with a longtime South San Francisco biotech company.
- GlobeNewswire
Cytokinetics to Announce Second Quarter Results on August 8, 2019
Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report second quarter results on August 8, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.
- GlobeNewswire
Cytokinetics Announces Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics
Cytokinetics, Incorporated (CYTK) today announced the publication of data in The Journal of Physiology demonstrating that a fast skeletal muscle troponin activator (FSTA) can decrease skeletal muscle fatigue by increasing the metabolic efficiency of muscle contraction. The manuscript, titled “Fast Skeletal Muscle Troponin Activator CK-2066260 Increases Fatigue Resistance by Reducing the Energetic Cost of Muscle Contraction,” was published this month. Cytokinetics conducted the research in collaboration with the laboratory of Professor Håkan Westerblad at the Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
- GlobeNewswire
Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy
Cytokinetics, Incorporated (CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of spinal muscular atrophy (SMA). In collaboration with Astellas, Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator (FSTA), as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.
- GlobeNewswire
Cytokinetics Announces Preclinical Data Relating to CK-3773274 to be Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
SOUTH SAN FRANCISCO, Calif., July 22, 2019 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that two preclinical poster presentations relating to CK-3773274.
- GlobeNewswire
Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Cytokinetics, Incorporated (CYTK) today announced the completion of patient enrollment in GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil which is being conducted by Amgen, in collaboration with Cytokinetics. Omecamtiv mecarbil, a novel investigational cardiac muscle activator, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.
- GlobeNewswire
Cytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference
Cytokinetics, Incorporated (CYTK) today announced that data from two preclinical studies of reldesemtiv were presented at the 2019 Annual Cure SMA Conference in Anaheim, CA, showing that the addition of reldesemtiv to treatment with SMN upregulators (nusinersen and SMN-C1, an analogue to risdiplam) significantly increased muscle force in a mouse model of spinal muscular atrophy (SMA). In collaboration with Astellas, Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator (FSTA), as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.
- Insider Monkey
Did Hedge Funds Drop The Ball On Cytokinetics, Inc. (CYTK) ?
Hedge fund interest in Cytokinetics, Inc. (NASDAQ:CYTK) shares was flat at the end of last quarter and it wasn't that high to begin with. This is usually a negative indicator. At the end of this article we will also compare CYTK to other stocks including The York Water Company (NASDAQ:YORW), Green Brick Partners Inc (NASDAQ:GRBK), […]
- GlobeNewswire
Cytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference
SOUTH SAN FRANCISCO, Calif., June 24, 2019 -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that two preclinical poster presentations on the addition of reldesemtiv.
- Simply Wall St.
Could The Cytokinetics, Incorporated (NASDAQ:CYTK) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Cytokinetics, Incorporated (NASDAQ:CYTK) can tell us which group is most powerful...
- GlobeNewswire
Cytokinetics to Present at the JMP Securities Life Sciences Conference
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 9:00 AM EST at the St. Regis Hotel in New York. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event.
